During the past decade, UCSD Moores Cancer Center conducted 65 clinical trials. In the 10-year time frame, 65 clinical trials started and 40 clinical trials were completed, i.e. on average, 61.5% percent of trials that started reached the finish line to date. In the past 5 years, 21 clinical trials started and 22 clinical trials were completed. i.e. 104.8% of trials that started reached the finish line.

Out of the total clinical trials conducted in "UCSD Moores Cancer Center" #1 sponsor was "University of California, San Diego" with 23 trials, followed by "Celgene" with 8 trials sponsored, "Hoffmann-La Roche" with 8 trials sponsored, "Bristol-Myers Squibb" with 6 trials sponsored and "Pfizer" with 6 trials sponsored. Other sponsors include 59 different institutions and companies that sponsored additional 57 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "UCSD Moores Cancer Center" #1 collaborator was "Merck Sharp & Dohme LLC" with 4 trials as a collaborator, "National Cancer Institute (NCI)" with 4 trials as a collaborator, "Pfizer" with 4 trials as a collaborator, "Genentech, Inc." with 3 trials as a collaborator and "University of California, San Diego" with 3 trials as a collaborator. Other collaborators include 49 different institutions and companies that were collaborators in the rest 56 trials.

According to Clinical.Site data, the most researched conditions in "UCSD Moores Cancer Center" are "Breast Cancer" (7 trials), "Cancer" (5 trials), "Head and Neck Cancer" (5 trials), "Melanoma" (5 trials) and "Chronic Lymphocytic Leukemia" (4 trials). Many other conditions were trialed in "UCSD Moores Cancer Center" in a lesser frequency.

Most popular intervention types in "UCSD Moores Cancer Center" are "Drug" (85 trials), "Biological" (16 trials), "Other" (6 trials), "Radiation" (5 trials) and "Behavioral" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (9 trials), "Atezolizumab" (6 trials), "Carboplatin" (5 trials), "Cetuximab" (5 trials) and "Gemcitabine" (5 trials). Other intervention names were less common.

The vast majority of trials in "UCSD Moores Cancer Center" are 99 trials for "All" genders, 9 trials for "Female" genders and 5 trials for "Male" genders.

Currently, there are 37 active trials in "UCSD Moores Cancer Center". 1 are not yet recruiting, 14 are recruiting, 21 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 56 completed trials in UCSD Moores Cancer Center, 2 suspended trials, and 14 terminated clinical trials to date.

Out of the total trials that were conducted in UCSD Moores Cancer Center, 28 "Phase 1" clinical trials were conducted, 58 "Phase 2" clinical trials and 23 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 6 trials that are defined as “Not Applicable".